Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214942 | 0.87 | CTSL (0.47) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL21598847 | 0.84 | OPRM1 (0.53) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL19635880 | 0.83 | OPRM1 (0.38) | OPRM1OPRL1DPP4SIGMAR1ALDH1A1 | |
| SCHEMBL27090796 | 0.79 | CARM1 (0.45) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL24652674 | 0.73 | NPC1 (0.58) | CTSLCTSBCTSKNAAASIGMAR1 | |
| SCHEMBL25399688 | 0.72 | CTSL (0.56) | DPP4CTSLCTSBCTSKALDH1A1 | |
| SCHEMBL11226960 | 0.72 | CTSL (0.60) | CTSLCTSBCTSKNAAASIGMAR1 | |
| SCHEMBL19181061 | 0.71 | CTSL (0.43) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL19779511 | 0.71 | ALDH1A1 (0.63) | SIGMAR1TMEM97CYP2C19ALDH1A1LMNA | |
| SCHEMBL28187918 | 0.71 | ALDH1A1 (0.63) | SIGMAR1TMEM97CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708165-B1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SINOMAB BIOSCIENCE LTD (CN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3459940-B1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SUZHOU SINOVENT PHARMACEUTICALS CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | SINOMAB BIOSCIENCE LIMITED (HK) | 2021-11-23 | — | — | US | disclosed |
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SUZHOU SINOVENT PHARMA CO., LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3708165-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | Sinomab Bioscience Limited (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3459940-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Zhejiang Yukon Pharma Co., Ltd. (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198049-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 浙江予川医药科技有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | BTK, SYK, LCK | OPRM1 4181/4885OPRL1 2730/4885DPP4 950/4885 |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | BTK, SYK, LCK | OPRM1 4512/4885OPRL1 3650/4885DPP4 2726/4885 |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | BTK, SYK, LCK | OPRM1 4512/4885OPRL1 3650/4885DPP4 2726/4885 |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | BTK, SYK, LCK | OPRM1 4181/4885OPRL1 2730/4885DPP4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.